NCT07156643

A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: NOT_YET_RECRUITING

Phase: PHASE2

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Condition: Locally Advanced Soft Tissue Sarcoma

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.